FRX vs. MDNA, ONC, SVA, KSI, VHI, DR, OGI, QIPT, CPH, and ACB
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Medicenna Therapeutics (MDNA), Oncolytics Biotech (ONC), Sernova (SVA), kneat.com (KSI), Vitalhub (VHI), Medical Facilities (DR), Organigram (OGI), Quipt Home Medical (QIPT), Cipher Pharmaceuticals (CPH), and Aurora Cannabis (ACB). These companies are all part of the "medical" sector.
Medicenna Therapeutics (TSE:MDNA) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations.
Medicenna Therapeutics has higher earnings, but lower revenue than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.
7.3% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 55.3% of Fennec Pharmaceuticals shares are held by institutional investors. 22.1% of Medicenna Therapeutics shares are held by company insiders. Comparatively, 14.6% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Medicenna Therapeutics had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 4 mentions for Medicenna Therapeutics and 3 mentions for Fennec Pharmaceuticals. Medicenna Therapeutics' average media sentiment score of 0.65 beat Fennec Pharmaceuticals' score of 0.17 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.
Medicenna Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.
Fennec Pharmaceuticals received 15 more outperform votes than Medicenna Therapeutics when rated by MarketBeat users. Likewise, 69.59% of users gave Fennec Pharmaceuticals an outperform vote while only 68.22% of users gave Medicenna Therapeutics an outperform vote.
Medicenna Therapeutics has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -75.50%. Fennec Pharmaceuticals' return on equity of -59.47% beat Medicenna Therapeutics' return on equity.
Summary
Medicenna Therapeutics beats Fennec Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
